Related Experiment Video
Updated: May 15, 2026
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease
Frederick S Buckner1, Julio A Urbina
1Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Insights
New drugs targeting sterol 14-demethylase (CYP51) show promise for treating Chagas disease. Research is ongoing to evaluate these CYP51 inhibitors for managing this prevalent parasitic infection.
Area of Science:
- Parasitology
- Infectious Diseases
- Drug Discovery
Background:
- Chagas disease, caused by Trypanosoma cruzi, is a major parasitic infection in the Americas, leading to severe health issues in approximately 30% of infected individuals.
- Current treatments for Chagas disease have limited efficacy and significant side effects, necessitating the development of improved therapeutic agents.
- The sterol biosynthesis pathway presents a viable target for novel anti-trypanosomal drug development.
Purpose of the Study:
- To investigate the potential of sterol 14-demethylase (CYP51) inhibitors as a therapeutic strategy against Trypanosoma cruzi infections.
- To review the preclinical and clinical progress of existing CYP51 inhibitors, including posaconazole and ravuconazole, for Chagas disease treatment.
- To highlight the ongoing development of novel, specifically optimized CYP51 inhibitors as alternatives to current antifungal drugs.
Main Methods:
- Review of preclinical data on the activity of antifungal azoles (e.g., posaconazole, ravuconazole) against Trypanosoma cruzi.
- Analysis of ongoing Phase II clinical studies evaluating posaconazole and a ravuconazole pro-drug (E1224) for Chagas disease.
- Assessment of academic research into novel CYP51 inhibitors tailored for anti-Trypanosoma cruzi activity.
Main Results:
- CYP51 inhibitors, particularly posaconazole and ravuconazole, have demonstrated significant in vitro and in vivo activity against Trypanosoma cruzi.
- Posaconazole and E1224 are currently undergoing clinical evaluation for Chagas disease, indicating promising therapeutic potential.
- Development of novel CYP51 inhibitors by academic institutions offers a promising alternative pipeline.
Conclusions:
- CYP51 inhibitors represent a highly promising class of drugs for the etiological treatment of Chagas disease.
- Ongoing clinical trials and the development of new inhibitors will define the future role of CYP51-targeted therapy.
- These agents could offer effective and potentially more accessible treatment options for Chagas disease patients, especially in endemic regions.
Abstract:
The protozoan parasite, Trypanosoma cruzi, causes the most prevalent parasitic infection in the American continent. It gives rise to life-long infection in humans and results in severe cardiomyopathy or other life-threatening manifestations (Chagas disease) in ~30% of those infected. Animal models and clinical studies indicate that etiological treatment of the infection reduces the risk of developing the disease manifestations. Unfortunately, the existing chemotherapeutics have suboptimal antiparasitic activity and cause significant side effects in many patients, thus better anti-trypanosomal drugs are greatly needed. The sterol biosynthesis pathway has received attention as a target for the development of new drugs for Chagas disease. In particular, inhibitors of sterol 14-demethylase (CYP51) are shown to be extremely active on Trypanosoma cruzi in vitro and in animal models. Antifungal drugs (i.e. azoles) in clinical use or in clinical studies have been extensively tested preclinically on Trypanosoma cruzi with posaconazole and ravuconazole demonstrating the most promising activity. As a result, posaconazole and a pro-drug of ravuconazole (E1224) are currently being evaluated in Phase II studies for Chagas disease. Additional CYP51 inhibitors that are specifically optimized for anti-Trypanosoma cruzi activity are in development by academia. These represent an alternative to proprietary antifungal drugs if the latter fall short in clinical trials or are too expensive for widespread clinical use in disease endemic countries. The research over the next few years will help define the role of CYP51 inhibitors, alone or in combination with other drugs, for managing patients with Chagas disease.
Related Concept Videos
01:15Anthelminthic Agents
01:29Pharmacogenomics: Identification of New Drug Targets